Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences

Sheila K. Patel, Jennifer A. Juno, Wen Shi Lee, Kathleen M. Wragg, P. Mark Hogarth, Stephen J. Kent, Louise M. Burrell
European Respiratory Journal 2021 57: 2003730; DOI: 10.1183/13993003.03730-2020
Sheila K. Patel
1Dept of Medicine, Austin Health, University of Melbourne, Melbourne, Australia
4Contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Juno
2Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
4Contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen Shi Lee
2Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen M. Wragg
2Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Mark Hogarth
3Immune Therapies Group, Burnet Institute, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J. Kent
2Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
5S.J. Kent and L.M. Burrell contributed equally to this article as lead authors and supervised the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise M. Burrell
1Dept of Medicine, Austin Health, University of Melbourne, Melbourne, Australia
5S.J. Kent and L.M. Burrell contributed equally to this article as lead authors and supervised the work
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louise M. Burrell
  • For correspondence: l.burrell@unimelb.edu.au
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Plasma ACE2 activity is persistently elevated in patients after COVID-19 infection. Larger studies are needed to determine if this identifies people at risk of prolonged illness following COVID-19. https://bit.ly/2XQlrYF

To the Editor:

Coronavirus disease 2019 (COVID-19) causes persistent endothelial inflammation, lung, cardiovascular, kidney and neurological complications, and thromboembolic phenomena of unclear pathogenesis [1]. Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) utilises the catalytic site of full-length membrane-bound angiotensin converting enzyme 2 (ACE2) for host cell entry [2], which is thought to downregulate membrane-bound ACE2, and thus contribute to ongoing inflammation due to loss of a degradative pathway for angiotensin II. In healthy individuals, ACE2 exists primarily in its membrane-bound form with very low levels of the catalytically active ectodomain of ACE2 present in the circulation [3]. However, in patients with cardiovascular disease, there is increased “shedding” of ACE2, and higher circulating levels are associated with downregulation of membrane-bound ACE2 [4].

In this prospective observational study in recovered COVID-19 patients, we hypothesised that SARS-CoV-2 infection would be associated with shedding of ACE2 from cell membranes leading to increased plasma ACE2 activity levels.

We measured plasma ACE2 catalytic activity using a validated, sensitive quenched fluorescent substrate-based in-house assay as previously described [3–5] in a cohort of Australians aged ≥18 years (n=66) who had recovered from mild, moderate or severe SARS-CoV-2 infection (positive result by PCR testing) and age- and gender-matched uninfected controls (n=70). Of the 66 recovered SARS-CoV-2 patients, 23 agreed to provide follow-up samples. The severity of COVID-19 infection was defined according to National Institutes of Health COVID-19 treatment guidelines [6] as mild (predominantly upper respiratory tract infection), moderate (lower respiratory tract infection) or severe (hospitalisation). The immune responses in a subset of the overall cohort in this paper have been previously reported [7], and for the purpose of this study, we also obtained information on medications and comorbid conditions including hypertension (diagnosis of hypertension and/or anti-hypertensive treatment), hyperlipidaemia (treatment with lipid lowering agents), obesity (body mass index ≥30 kg·m−2), diabetes and cardiovascular disease. The study was approved by the University of Melbourne Human Research Ethics Committee (#2056689); all participants provided written informed consent in accordance with the Declaration of Helsinki.

Data were analysed with SPSS version 26.0 (IBM SPSS Statistics, IBM Corp., USA). Plasma ACE2 activity was compared using the Mann–Whitney test or Kruskal–Wallis test and significance adjusted by Bonferroni correction for multiple tests. Fisher's exact test was used to compare categorical variables. Serial ACE2 activity levels were analysed using the Friedman test for repeated measures; after post hoc analysis with Wilcoxon signed-rank tests with a Bonferroni correction applied. Two-tailed p-values <0.05 were considered significant.

The controls and SARS-CoV-2 recovered subjects were matched for age (mean±sd 54±11 versus 53±14 years; p=0.47) and gender (37 (53%) versus 39 (59%) male; p=0.49). With regard to risk factors and/or comorbidities, hypertension was present in 7% (n=9) of all subjects, hyperlipidaemia in 8% (n=11), obesity in 2% (n=3), diabetes in 1% (n=1) and cardiovascular disease in 2% (n=3), with no difference between controls and SARS-CoV-2 recovered subjects (all, p>0.05). There was no difference in the use of antihypertensive (n=7), lipid lowering (n=11) or antiplatelet therapy (n=4) between controls and SARS-CoV-2 recovered subjects (all, p>0.05).

At a median of 35 days post-infection (interquartile range 30–38 days), plasma ACE2 activity was significantly higher in recovered SARS-CoV-2 subjects compared to controls (5.8 (2–11.3) versus 0.06 (0.02–2.2) pmol·min−1·mL−1; p<0.0001) (figure 1a). Plasma ACE2 activity differed according to disease severity (p=0.033), with severe COVID-19 associated with higher ACE2 activity compared to mild disease (11.2 (8.3–23.2) versus 5.4 (1.8–9.0) pmol·min−1·mL−1; p=0.027) (figure 1b). Men (n=39) who were SARS-CoV-2-positive had higher median plasma ACE2 levels compared to women (n=27) (9.2 (5.8–15.3) versus 2.1 (0.2–5.1) pmol·min−1·mL−1; p<0.0001). The observation that plasma ACE2 is higher in men compared to women is consistent with our previous findings in non-COVID-19 patients with coronary artery disease [5], and in the general population [8].

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Plasma angiotensin converting enzyme 2 (ACE2) activity is elevated in patients who recovered from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (a), is increased with disease severity (b), and remains elevated 2–3 months after SARS-CoV-2 infection. Data shown as scatter points and box plot with whiskers representing minimum and maximum values of median plasma ACE2 activity between controls, and patients who recovered from SARS-CoV-2 infection (a) and median plasma ACE2 activity in patients recovered from SARS-CoV-2 infection according to disease severity (b). The median (interquartile range) plasma ACE2 activity levels are shown above each bar. The median plasma ACE2 activity in patients recovered from SARS-CoV-2 infection with serial samples (n=23) at three time-points (indicated by median (interquartile range) days after positive PCR test) are shown in (c). The median (interquartile range) plasma ACE2 activity levels are shown above the bar for each time-point. Two-tailed p-values <0.05 were considered significant.

We next analysed whether elevated plasma ACE2 activity persisted following SARS-CoV-2 infection in 23 subjects who provided further blood samples at 63 (56–65) and 114 (111–125) days post-infection. This subset was representative of the overall cohort for age (52±15 years), gender (14 (61%) male) and disease severity (mild 15 (65%), moderate 5 (22%), severe 3 (13%)). Plasma ACE2 activity remained persistently elevated in almost all subjects (figure 1c), with no significant differences between time-points in post hoc comparisons (p>0.05). There was no change in plasma ACE2 activity in control subjects with serial samples (n=8; timepoint 1: 0.8 (0.02–3.0); versus timepoint 2: 1.4 (0.02–5.9) pmol·min−1·mL−1; p=0.31).

This is the first description that plasma ACE2 activity is elevated in patients after COVID-19 infection compared to uninfected age- and gender-matched controls with similar comorbidities, and the first with long-term data to indicate that plasma ACE2 activity remains elevated out to a median of 114 days post-infection, the last time-point sampled. It is already known that males have higher plasma ACE2 activity than females [5, 8], but this is the first report that plasma ACE2 activity levels are increased in those with more severe COVID-19 infection. Although the pathophysiological causes and consequences of elevated plasma ACE2 activity in the setting of COVID-19 are unknown, we have reported that increased plasma ACE2 was an independent risk factor for major adverse cardiac events in patients with aortic stenosis [4] and coronary artery disease [5]. Others have recently shown that higher plasma ACE2 concentration was associated with increased risk of major cardiovascular events in a large global population-based study [8].

In conclusion, we suggest that binding of SARS-CoV-2 to membrane ACE2 has at least two effects. First, it downregulates membrane ACE2 causing a dysregulated local renin angiotensin system (RAS) that favours inflammation and ongoing tissue damage secondary to excess angiotensin II [9]. Second, the dysregulated local RAS is associated with prolonged shedding of the catalytically active site of ACE2 into the circulation.

In addition to the early multisystem effects of COVID-19, a proportion of patients experience prolonged ill-health commonly known as “long-COVID”, the nature of which remains to be fully characterised [10]. Larger studies are now needed to determine if persistently elevated plasma ACE2 activity may identify people at risk of prolonged illness or cardiac events following COVID-19 infection, as well as studies that address whether therapeutic strategies directed at a dysregulated RAS can reduce COVID-19 complications.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-03730-2020.Shareable

Acknowledgements

We thank the generous participation of the study subjects for providing samples. We thank Adam Wheatley, Jane Batten and Helen Kent for help with the COVID-19 cohort, and Ping Huang and Thomas McConville for assistance with the ACE2 activity assays.

Footnotes

  • Conflict of interest: S.K. Patel has nothing to disclose.

  • Conflict of interest: J.A. Juno has nothing to disclose.

  • Conflict of interest: W.S. Lee has nothing to disclose.

  • Conflict of interest: K.M. Wragg has nothing to disclose.

  • Conflict of interest: P.M. Hogarth reports grants from National Health and Medical Research Council (Australia) during the conduct of the study; grants from Genmab (b.v.), outside the submitted work.

  • Conflict of interest: S.J. Kent has nothing to disclose.

  • Conflict of interest: L.M. Burrell has nothing to disclose.

  • Support statement: This study was supported by the Victorian Government (S.J. Kent, J.A. Juno), an Australian government Medical Research Future Fund award GNT2002073 (S.J. Kent, P.M. Hogarth), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology CE140100036 (S.J. Kent), NHMRC programme grants APP1149990 (S.J. Kent) and APP 1055214 (L.M. Burrell), project grant GNT1145303 (P.M. Hogarth), Medical Research Future Fund award GNT 1175865 (S.K. Patel, L.M. Burrell), Austin Medical Research Foundation Grant (S.K. Patel, L.M. Burrell). J.A. Juno and S.J. Kent are supported by NHMRC fellowships. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received October 6, 2020.
  • Accepted January 3, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Huang C,
    2. Wang Y,
    3. Li X, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5
    OpenUrlCrossRefPubMed
  2. ↵
    1. Hoffmann M,
    2. Kleine-Weber H,
    3. Schroeder S, et al.
    SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280. doi:10.1016/j.cell.2020.02.052
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lew RA,
    2. Warner FJ,
    3. Hanchapola I, et al.
    Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93: 685–693. doi:10.1113/expphysiol.2007.040352
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Ramchand J,
    2. Patel SK,
    3. Kearney LG, et al.
    Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging 2020; 13: 655–664. doi:10.1016/j.jcmg.2019.09.005
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ramchand J,
    2. Patel SK,
    3. Srivastava PM, et al.
    Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One 2018; 13: e0198144. doi:10.1371/journal.pone.0198144
    OpenUrlCrossRefPubMed
  6. ↵
    COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. www.covid19treatmentguidelines.nih.gov/ Date last accessed: 23 December 2020.
  7. ↵
    1. Juno JA,
    2. Tan HX,
    3. Lee WS, et al.
    Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 2020; 26: 1428–1434. doi:10.1038/s41591-020-0995-0
    OpenUrlCrossRef
  8. ↵
    1. Narula S,
    2. Yusuf S,
    3. Chong M, et al.
    Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet 2020; 396: 968–997. doi:10.1016/S0140-6736(20)31964-4
    OpenUrl
  9. ↵
    1. Ramchand J,
    2. Burrell LM
    . Circulating ACE2: a novel biomarker of cardiovascular risk. Lancet 2020; 396: 937–939. doi:10.1016/S0140-6736(20)32011-0
    OpenUrl
  10. ↵
    1. Yelin D,
    2. Wirtheim E,
    3. Vetter P, et al.
    Long-term consequences of COVID-19: research needs. Lancet Infect Dis 2020; 20: 1115–1117. doi:10.1016/S1473-3099(20)30701-5
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 5 Table of Contents
European Respiratory Journal: 57 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences
Sheila K. Patel, Jennifer A. Juno, Wen Shi Lee, Kathleen M. Wragg, P. Mark Hogarth, Stephen J. Kent, Louise M. Burrell
European Respiratory Journal May 2021, 57 (5) 2003730; DOI: 10.1183/13993003.03730-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences
Sheila K. Patel, Jennifer A. Juno, Wen Shi Lee, Kathleen M. Wragg, P. Mark Hogarth, Stephen J. Kent, Louise M. Burrell
European Respiratory Journal May 2021, 57 (5) 2003730; DOI: 10.1183/13993003.03730-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Normative multiple-breath washout data for children corrected for sensor error
Show more Agora

Research letters

  • Lessons from 2 years of use of the Post-COVID-19 Functional Status scale
  • Beta-blockade improves right ventricular diastolic function in exercising PAH
  • Trends in COVID-19-associated mortality in PH
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society